Researchers found limited clinical variability between PIV serotypes and substantial overlap in presenting signs and symptoms for PIV and other etiologies.
A phase 3 study of tocilizumab (Actemra®) for the treatment of hospitalized patients with severe COVID-19 pneumonia did not meet its primary and key secondary end points.
The FDA has granted Orphan Drug designation to INO-3107, a DNA plasmid immunotherapy, for the treatment of recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus types 6 and 11 infections.
New clinical practice guidelines for the treatment of nontuberculous mycobacterial pulmonary disease were published by leading respiratory medicine and infectious disease societies.
Study finds that patients with IBD and 1 or more comorbidities are at increased risk for viral or bacterial meningitis.
Influenza hospitalizations were decreased among people with diabetes when vaccines were received in multiple influenza seasons.
A shorter regimen of rifampin is safer and less expensive than the standard 9-month regimen of isoniazid for treatment latent tuberculosis.
In immunocompromised adults, community-acquired pneumonia should be treated by a multidisciplinary team of physicians.
Study reveals no evidence for an association between first-trimester vaccination and major malformations or congenital heart defects in infants.
Study data support the use of therapeutic antibodies targeting IL-17A, such as ixekizumab, in patients with latent tuberculosis infection.
Treatment with daptomycin for bacteremia caused by methicillin-resistant Staphylococcus aureus complicated by septic pulmonary emboli was found to have a success rate comparable to daptomycin-ceftaroline fosamil.
A team of investigators conducted a retrospective cohort study to determine the risk of subdeltoid bursitis associated with the administration of the influenza vaccine.
Respiratory viral coinfection occurs substantially more frequently in children, especially in those aged <5 years.
A study revealed that primary care clinicians do not closely follow clinical practice guidelines with regard to antibiotic prescribing for acute sinusitis and frequently overprescribe antibiotics.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
Pneumoconiosis deaths decreased by 40.4 percent during 1999 to 2018.
Risk factors for bronchiectasis in patients with AERD include older age as well as the presence of allergic bronchopulmonary aspergillosis, aspiration, mycobacterial infection, and pneumonia.
Patients with COVID-19 pneumonia may present with 2 distinct phenotypes, each warranting distinct treatments.
Among college students, human adenoviruses should be considered as a cause for respiratory illness.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).